Compare Gilead Sciences, Inc. (GILD) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Koninklijke Philips NV — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.09B), while Koninklijke Philips NV trades at $24.3 (market cap $23.68B). The key difference: Gilead Sciences, Inc. is far larger — about 7.7× Koninklijke Philips NV's market cap, and Koninklijke Philips NV pays the higher dividend (4.21%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Koninklijke Philips NV for 84 Days on average.
| GILD | PHG | |
|---|---|---|
Market Cap | $182.09B | $23.68B |
Volume | 4,960,247 | 1,443,075 |
Sector | Health | Health |
52-Week High | $155.80 | $32.91 |
52-Week Low | $116.74 | $23.81 |
Typical Hold Time | 111 Days | 84 Days |
Enterprise Value | $205.15B | $30.07B |
Dividend Yield | 2.23% | 4.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
PHG trades at $24.30, up 0.62% with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with net income turning positive to $895M in 2025 after previous losses, supported by strong operational cash flow of $1.17B. Analyst consensus leans Hold (63.64%) while institutional activity remains active with recent purchases by Bank of America and Arrowstreet Capital.
The outlook balances recovery momentum against technical weakness. Investment opportunity lies in continued earnings improvement and new product launches, while risks include competitive pressures and the bearish technical trend. Debt levels remain manageable with debt-to-asset ratio at 25.44% as of 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
